Evogene's Herbicide Project with Bayer Terminated Due to Failed Target Protein

summarizeSummary

Evogene's subsidiary Ag Plenus and Bayer have terminated their herbicide development project, citing the target protein's failure to meet product criteria, a significant blow to Evogene's R&D pipeline amidst its ongoing financial and compliance challenges.

check_boxKey Events

• Herbicide Project Termination

  Evogene's subsidiary Ag Plenus Ltd. and Bayer AG have mutually decided to discontinue their herbicide development project, effective May 18, 2026.

• Failure to Meet Criteria

  The project was terminated because the target protein, APTH1, did not meet the required product criteria, indicating a setback in the R&D pipeline.

• Asset Reversion

  All licensed assets, including the APTH1 protein target and associated active molecules, will revert to Ag Plenus under the terms of the termination.

• Context of Company Distress

  This development comes as Evogene faces substantial doubt about its going concern status and has received a formal Nasdaq delisting notice for non-compliance with the minimum bid price rule.

auto_awesomeAnalysis

The discontinuation of a key herbicide development project with Bayer is a significant setback for Evogene, especially given the company's current precarious financial position and recent Nasdaq delisting notice. For a company heavily reliant on its R&D pipeline, the failure of a collaboration with a major partner like Bayer due to unmet product criteria raises serious questions about its future product viability and ability to generate revenue. While the assets revert, the inability to progress a promising project adds to the negative sentiment surrounding the company's operational and financial health.